This clinical trial studies the side effects and how well brain-avoidant (BRAVO) proton craniospinal irradiation (pCSI) works in treating patients with solid tumor malignancies that have spread from where they first started (primary site) to the spinal fluid around the brain and spinal cord (leptomeninges metastases [LM]). One of the most effective treatments for LM is pCSI which treats the entire brain and spinal cord with radiation. However, pCSI causes long-term changes in the brain and reduces the ability to learn and remember new things. BRAVO pCSI is a modified pCSI approach which avoids treating the parts of the brain that are most important for learning and memory, including an area called the hippocampus. BRAVO pCIS may be an effective way to treat LM from solid tumor malignancies and may also protect learning and memory.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07789912.
Locations matching your search criteria
United States
Florida
Miami
University of Miami Miller School of Medicine-Sylvester Cancer CenterStatus: Active
Contact: Morgan Freret
Phone: 305-243-5470
PRIMARY OBJECTIVE:
I. To evaluate central nervous system (CNS) progression free survival (PFS) after brain-avoidant proton CSI (BRAVO pCSI) treatment of patients with LM from breast cancer and/or non-small cell lung cancer (NSCLC) (group 1) and from other solid tumor histologies (group 2).
SECONDARY OBJECTIVES:
I. To evaluate the overall survival (OS) after BRAVO pCSI in each group.
II. To determine treatment response rates after BRAVO pCSI in each group.
III. To evaluate the safety and tolerability of BRAVO pCSI in each group and in a pooled analysis.
IV. To assess the rate of cognitive failure after BRAVO pCSI at 3 months (+4 weeks) as compared to baseline in each group and in a pooled analysis of groups 1 and 2.
V. To assess patient-reported fatigue, depression and quality of life as per the Schedule of Assessments (SoA) in each group and in a pooled analysis of groups 1 and 2.
EXPLORATORY OBJECTIVES:
I. To assess the association between treatment response and circulating tumor cells (CTCs) in blood and cerebrospinal fluid (CSF).
II. To assess the association between treatment response and cell-free deoxyribonucleic acid (DNA) (cfDNA) levels in plasma and CSF.
III. To evaluate feasibility of ribonucleic acid (RNA) and protein analysis of the CSF cellular components.
IV. To assess the association between treatment response and tumor markers in blood and in CSF.
OUTLINE: Patients are assigned to 1 of 3 groups.
GROUP 1: Patients with LM from breast cancer or NSCLC undergo ten treatment fractions of BRAVO pCSI once daily (QD), Monday-Friday, over 2 weeks in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo computed tomography (CT) or positron emission tomography (PET)/CT during screening and blood and CSF sample collection as well as magnetic resonance imaging (MRI) throughout the study.
GROUP 2: Patients with LM from solid tumors of other histologies undergo ten treatment fractions of BRAVO pCSI QD, Monday-Friday, over 2 weeks in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or PET/CT during screening and blood and CSF sample collection as well as MRI throughout the study.
GROUP 3: Patients with LM who decline BRAVO pCSI undergo baseline and follow-up assessments. Additionally, patients undergo CT or PET/CT during screening and blood and CSF sample collection as well as MRI throughout the study.
After completion of study treatment, patients are followed up at 6 weeks, 3 months, 6 months, 12 months, and then periodically per standard of care.
Trial PhaseNo phase specified
Trial Typetreatment
Lead OrganizationUniversity of Miami Miller School of Medicine-Sylvester Cancer Center
Principal InvestigatorMorgan Freret